Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).

Publisher: Published by BMJ in partnership with the American Diabetes Association Country of Publication: England NLM ID: 101641391 Publication Model: eCollection Cited Medium: Internet ISSN: 2052-4897 (Electronic) Linking ISSN: 20524897 NLM ISO Abbreviation: BMJ Open Diabetes Res Care Subsets: MEDLINE

Original Publication: London : Published by BMJ in partnership with the American Diabetes Association

Quality of Life*; Biomarkers/*blood ; Blood Glucose Self-Monitoring/*methods ; Blood Glucose Self-Monitoring/*statistics & numerical data ; Diabetes Mellitus, Type 1/*blood ; Diabetes Mellitus, Type 2/*blood ; Hypoglycemic Agents/*therapeutic use; Adult ; Blood Glucose/analysis ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 1/pathology ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/pathology ; Female ; Follow-Up Studies ; Glycated Hemoglobin/analysis ; Humans ; Hypoglycemia/prevention & control ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Prognosis ; Prospective Studies

Introduction: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden.
Methods: Prospective nationwide registry. Participants with diabetes mellitus (DM) used the FSL-FGM system for a period of 12 months. End points included changes in HbA1c, hypoglycemia, health-related quality of life (12-Item Short Form Health Survey ^v2 (SF-12 ^v2 ) and 3-level version of EuroQol 5D (EQ-5D-3L)), a specifically developed patient-reported outcome measures (PROMs) questionnaire, diabetes-related hospital admission rate and work absenteeism. Measurements were performed at baseline, and after 6 months and 12 months.
Results: 1365 persons (55% male) were included. Mean age was 46 (16) years, 77% of participants had type 1 DM, 16% type 2 DM and 7% other forms. HbA1c decreased from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 to 61) mmol/mol with a difference of -4 (95% CI -6 to 3) mmol/mol. Persons with a baseline HbA1c >70 mmol/mol had the most profound HbA1c decrease: -9 (95% CI -12 to to 5) mmol/mol. EQ-5D tariff (0.03 (95%CI 0.01 to 0.05)), EQ-VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12 ^v2 mental component score (3.3 (95%CI 2.1 to 4.4)) improved. For most, PROMs improved. Work absenteeism rate (/6 months) and diabetes-related hospital admission rate (/year) decreased significantly, from 18.5% to 7.7% and 13.7% to 2.3%, respectively.
Conclusions: Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

BMJ Open Diabetes Res Care. 2017 Feb 17;5(1):e000320. (PMID: 28243449)
Ned Tijdschr Geneeskd. 2005 Jul 9;149(28):1574-8. (PMID: 16038162)
N Engl J Med. 2019 Feb 28;380(9):801-803. (PMID: 30811905)
Lancet. 1998 Sep 12;352(9131):854-65. (PMID: 9742977)
Res Nurs Health. 2017 Aug;40(4):378-386. (PMID: 28732149)
Qual Life Res. 2005 Apr;14(3):655-63. (PMID: 16022059)
Diabetes Ther. 2020 Jan;11(1):279-291. (PMID: 31833041)
N Engl J Med. 2005 Dec 22;353(25):2643-53. (PMID: 16371630)
Contact Dermatitis. 2018 Dec;79(6):331-335. (PMID: 30264920)
Diabetologia. 2019 Aug;62(8):1349-1356. (PMID: 31177314)
Diabetes Care. 2019 Sep;42(9):1669-1674. (PMID: 31213468)

Keywords: continuous glucose monitoring; flash glucose monitoring; freestyle libre; patient reported outcome measures; type 1 diabetes

0 (Biomarkers)
0 (Blood Glucose)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
0 (hemoglobin A1c protein, human)

Date Created: 20191226 Date Completed: 20200910 Latest Revision: 20231020

20240628

PMC6904165

10.1136/bmjdrc-2019-000809

31875133